Table 1.
Baseline characteristics of patients according to proportion of time in therapeutic range.
Table 2.
Proportion of patients with TTR <65% and ≥65% in different geographic regions.
Table 3.
Proportion of time in therapeutic range (%) for patients on different vitamin K antagonists*.
Table 4.
Proportion of time in therapeutic range (%) for patients on vitamin K antagonists with and without concomitant antiplatelet therapy.
Fig 1.
Incidence rates and adjusted hazard ratios for 1-year clinical outcomes according to proportion of time in therapeutic range.
Reference group: TTR≥65%. Incidence rates are per 100 person-years. CI, confidence interval; HR, hazard ratio; SE, systemic embolism; TTR, time in therapeutic range. HRs were controlled for the following potential confounders: age group (≤64, 65–69, 70–74, ≥75 years), gender, smoking (no, ex, current), congestive heart failure, vascular disease, moderate-to-severe chronic kidney disease, diabetes mellitus, hypertension, previous stroke (not included in the model for major bleeding events), previous bleeding (not included in the model for stroke/SE), antiplatelet treatment, type of atrial fibrillation, and area (Europe, Asia, other countries).
Table 5.
Adjusted hazard ratios for 1-year clinical outcomes by proportion of time in therapeutic range for the main analysis and sensitivity analysis (excluding international normalised ratio readings and events during the first 3 months of treatment).
Table 6.
Four-month event rates in patients with proportion of time in therapeutic range <65% and ≥65%.
Fig 2.
Four-month rate ratios by proportion of time in therapeutic range for (A) stroke/systemic embolism, (B) major bleeding, and (C) all-cause mortality.
SE, systemic embolism; TTR, time in therapeutic range.